Papa John's Incident: A false report of a $65-per-share acquisition offer for Papa John's led to significant stock volatility, with shares rising 18% before settling at a 7.04% increase.
Vinci SA Case: In November 2016, Vinci SA's stock plummeted over 18% due to a fake press release claiming the company had fired its CFO and discovered hidden losses, which was later denied.
Avon Products Hoax: A fraudulent SEC filing in May 2015 falsely claimed a buyout offer for Avon Products, causing a 20% stock spike before the company confirmed the offer was fake.
Galena Biopharma Scheme: A 2017 SEC complaint revealed a complex "pump-and-dump" scheme involving paid articles that inflated Galena Biopharma's stock price by over 900%, misleading both investors and trading algorithms.
Wall Street analysts forecast SLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLS is 7.25 USD with a low forecast of 7.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast SLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLS is 7.25 USD with a low forecast of 7.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.510
Low
7.00
Averages
7.25
High
7.50
Current: 4.510
Low
7.00
Averages
7.25
High
7.50
Maxim
Maxim
Buy
maintain
$4 -> $7
2025-07-16
Reason
Maxim
Maxim
Price Target
$4 -> $7
AI Analysis
2025-07-16
maintain
Buy
Reason
Maxim raised the firm's price target on Sellas Life Sciences to $7 from $4 and keeps a Buy rating on the shares. Shares have risen about 90% year-to-date as the company continues to execute across its Acute Myeloid Leukemia, or AML, programs, the analyst tells investors in a research note. Maxim further cites the company's galinpepimut-S in Phase 3 and yesterday's positive SLS009 data hitting all its endpoints, adding that its higher price target factors in SLS009 in first-line AML as a potential triplet combination with venetoclax/azacitidine.
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
